Dr Susan Orr is an experienced medical and business leader specialising in identifying, developing, and commercialising ophthalmic therapeutic product candidates.
Dr Orr has been the chief medical officer of Claris Biotherapeutics since February 2020, and is a member of the Retina Global board of directors. Prior to joining Claris, Dr Orr was the chief executive of Notal Vision. She had spent more than 30 years in the field of ophthalmology that also includes ten years in private optometric practice and leadership roles at Alcon and Janssen spanning international development, global new product strategy, and business development and licensing.
Dr Orr participated in multiple acquisitions including Durezol and Beovu (brolucizumab), and has been a managing partner of Fovendeye Consulting since 2016.
